STOCK TITAN

Lexaria Bioscience Corp. - LEXX STOCK NEWS

Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a pioneering company in the field of drug delivery technology. The company has developed and patented a unique drug delivery platform known as DehydraTECH™, which enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. This technology is notable for significantly improving bio-absorption rates, reducing the onset time of drugs, and masking unpleasant tastes.

DehydraTECH™ has demonstrated remarkable efficacy in enhancing the bio-absorption of cannabinoids and nicotine, increasing their uptake by 5-10 times, and in some cases, by as much as 27 times compared to traditional formulations. This technology also shows potential in improving the delivery of certain drugs through the blood-brain barrier, making it particularly valuable for drugs targeting the central nervous system.

The company operates four key segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. Intellectual Property Licensing is the primary revenue generator for Lexaria, leveraging its robust portfolio of 43 granted patents and numerous pending patents worldwide.

Lexaria's recent endeavors include a series of human and animal studies focused on the application of DehydraTECH™ in enhancing the delivery and efficacy of GLP-1 drugs. These drugs, such as semaglutide and tirzepatide, are primarily used for treating diabetes and promoting weight loss. The company has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics and performance of DehydraTECH-processed GLP-1 drugs.

The latest human pilot studies have shown promising results, including higher drug delivery and better blood glucose control with fewer side effects. The company is also exploring the use of DehydraTECH™ for other APIs like cannabidiol (CBD), with applications in treating hypertension and epilepsy.

Recent financial activities include a warrant exercise agreement, raising approximately $4.7 million, which bolsters Lexaria's operational runway into 2025. This financial stability allows the company to pursue its aggressive research and development plans.

Lexaria's innovative approach and continuous research efforts position it as a significant player in the drug delivery technology sector, with the potential to form strategic partnerships with leading pharmaceutical companies.

Rhea-AI Summary

Lexaria Bioscience Corp (NASDAQ:LEXX) provides an update on the GLP-1 industry and its strategic positioning. The company is developing its DehydraTECH™ drug delivery platform for application in the GLP-1 space, aiming to position it as essential technology for pharmaceutical companies. The GLP-1 sector has seen significant M&A activity, with major pharmaceutical companies like Novo Nordisk and Eli Lilly making substantial investments. Recent deals include Novo's $285 million license agreement with Ascendis Pharma, a $600 million collaboration with NanoVation Therapeutics, and the $1.08 billion acquisition of Inversago Pharma. The sector is projected to generate between $100 billion to $471 billion in annual revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience (NASDAQ:LEXX) announces partial 12-week blood sugar results from their animal study WEIGHT-A24-1. The study evaluated DehydraTECH-processed formulations of CBD, liraglutide, semaglutide, and Rybelsus. Among eight study groups, DehydraTECH-liraglutide (Group H) showed the most significant reduction in blood sugar levels (-11.54%), followed by DehydraTECH-CBD Group B (-3.76%). This marks the first-ever evaluation of DehydraTECH-processed liraglutide, with notably strong performance compared to other groups. Additional data, including body weight, blood glucose findings, and pharmacokinetic results, are pending from third-party laboratories.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX) has released partial 12-week body weight results from its animal study WEIGHT-A24-1. The study evaluated various DehydraTECH formulations, including CBD and GLP-1 drugs. Key findings include:

1. DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top-performing weight loss groups.

2. All DehydraTECH groups experienced accelerated rates of weight loss during the final 4 weeks of the study.

3. DehydraTECH-liraglutide outperformed DehydraTECH-semaglutide, which is notable given semaglutide's typically higher effectiveness in humans.

4. Lexaria has filed patent applications for the unique performance of liraglutide processed with DehydraTECH.

The company awaits additional data, including blood glucose findings and pharmacokinetic results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) has closed a $5 million registered direct offering priced at-the-market under Nasdaq rules. The offering included the sale of 1,633,987 shares of common stock at $3.06 per share. Additionally, the company issued unregistered warrants to purchase up to 4,551,019 shares at an exercise price of $3.06 per share in a concurrent private placement.

The warrants will be exercisable after stockholder approval and expire five years from that date. H.C. Wainwright & Co. acted as the exclusive placement agent. Lexaria plans to use the net proceeds for working capital and general corporate purposes. The offering was made under a shelf registration statement, and a final prospectus supplement was filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced a $5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 1,633,987 shares of common stock at $3.06 per share. Additionally, Lexaria will issue unregistered warrants to purchase up to 4,551,019 shares at the same price in a concurrent private placement.

The warrants will be exercisable after stockholder approval and expire five years later. H.C. Wainwright & Co. is the exclusive placement agent. The offering is expected to close around October 16, 2024. Lexaria plans to use the net proceeds for working capital and general corporate purposes. Upon closing, 2,917,032 outstanding warrants issued in April 2024 will be cancelled.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX) has initiated dosing for its third human pilot study, investigating an oral dose format of DehydraTECH-processed tirzepatide from Zepbound®. The study involves up to 10 healthy volunteers and consists of two seven-day dosing phases with a multi-week washout period in between. The first phase is set to conclude on October 13, 2024, with the second phase to begin in mid-November. No serious adverse events have been reported. The study will evaluate tolerability, blood absorption levels, and blood sugar control. Tirzepatide, marketed under Zepbound® and Mounjaro® by Eli Lilly™, is expected to generate $15 billion in 2024. Lexaria aims to demonstrate significant absorption rates for oral tirzepatide, building on previous studies showing improved absorption and reduced adverse events for DehydraTECH-processed semaglutide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
News
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX) provides an update on the rapidly growing GLP-1 receptor agonist market. The market has expanded from less than $4 billion in 2020 to a projected $44.5-$49.3 billion in 2024, with analysts forecasting up to $471.1 billion by 2033. Currently, over 95% of the market is dominated by two drugs: semaglutide and tirzepatide. The oral tablet form of these drugs, which currently comprises only 10% of the market, is expected to grow significantly.

Lexaria's DehydraTECH drug delivery system aims to lead in oral GLP-1/GIP drug delivery. Recent studies have shown GLP-1 drugs' potential in reducing cardiovascular risks and improving outcomes for chronic kidney disease patients, suggesting possible expanded therapeutic applications in the future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX & LEXXW) has appointed Michael Shankman, CPA, as its new Chief Financial Officer (CFO), effective immediately. Mr. Shankman brings extensive financial and regulatory experience to the role, having previously worked with Lexaria on financial reporting and auditing. From 2021 to 2024, he provided outsourced CFO and Controller services for various public and private companies across multiple industries.

CEO Richard Christopher expressed enthusiasm about the appointment, citing Shankman's accomplishments and the company's expectations for strong growth into 2025. Shankman himself expressed excitement about joining Lexaria, noting the company's potential for advancements and his eagerness to contribute to its pharmaceutical research and development program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
management
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has received independent review board approval for human pilot study #3, investigating a DehydraTECH-processed version of tirzepatide in an oral dose format. The study will compare a single injected dose of Zepbound® (tirzepatide) to 7 consecutive days of daily oral dosing of DehydraTECH-processed Zepbound® in up to 10 healthy volunteers.

The study will evaluate tolerability, blood absorption levels, and blood sugar control. Lexaria aims to demonstrate meaningful absorption rates of tirzepatide in a swallowed oral format, which is currently unavailable in the market. The company expects to begin subject recruitment shortly, with first dosing anticipated in late October and final doses in late November.

Additionally, Lexaria's CRO has submitted information for ethics review of the 12-week study GLP-1-H24-4, expected to be a Phase 1b registrational study by the FDA, with first-in-patient dosing anticipated this winter in Australia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX) announces a strategic update as CEO Chris Bunka steps down. Key points include:

  • New focus on pharmaceutical studies in cardiometabolic and GLP-1 sectors
  • Appointment of Richard Christopher as new CEO with pharma/biotech operations experience
  • FDA clearance for Phase 1b hypertension study using DehydraTECH-CBD
  • Over $8.5 million raised in 2024 through equity raises and warrant exercises
  • Market cap growth from $5 million in June 2023 to $60 million
  • Ongoing GLP-1 studies with promising results
  • Plans for two Phase 1 studies in 2025
  • Material Transfer Agreement with a pharmaceutical company

Bunka will continue as Executive Strategic Advisor and Chairman of the Board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none

FAQ

What is the current stock price of Lexaria Bioscience (LEXX)?

The current stock price of Lexaria Bioscience (LEXX) is $2.21 as of December 24, 2024.

What is the market cap of Lexaria Bioscience (LEXX)?

The market cap of Lexaria Bioscience (LEXX) is approximately 38.6M.

What is Lexaria Bioscience Corp. known for?

Lexaria Bioscience Corp. is renowned for its patented DehydraTECH™ drug delivery technology, which enhances the bio-absorption of active pharmaceutical ingredients.

How does DehydraTECH™ improve drug delivery?

DehydraTECH™ enhances drug delivery by increasing bio-absorption rates, reducing the onset time, and masking unpleasant tastes of active pharmaceutical ingredients.

What are the main business segments of Lexaria?

Lexaria operates four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate.

What recent achievements has Lexaria accomplished?

Recently, Lexaria has shown promising results in human and animal studies using DehydraTECH™ for GLP-1 drugs and raised approximately $4.7 million through a warrant exercise agreement.

What are some key applications of DehydraTECH™?

Key applications of DehydraTECH™ include enhancing the delivery of cannabinoids, nicotine, and GLP-1 drugs, as well as potential uses in hypertension and epilepsy treatments.

How many patents does Lexaria hold?

Lexaria holds a robust portfolio with 43 granted patents and many patents pending worldwide.

What partnerships has Lexaria recently engaged in?

Lexaria has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics of DehydraTECH-processed GLP-1 drugs.

What financial activities has Lexaria recently undertaken?

Lexaria recently entered into a warrant exercise agreement, raising approximately $4.7 million to support its operational and R&D activities into 2025.

How does DehydraTECH™ benefit centrally active compounds?

DehydraTECH™ enhances the delivery of drugs across the blood-brain barrier, which is particularly important for centrally active compounds.

Where can I find more information about Lexaria?

For more information, you can visit Lexaria Bioscience Corp.'s official website at www.lexariabioscience.com.

Lexaria Bioscience Corp.

Nasdaq:LEXX

LEXX Rankings

LEXX Stock Data

38.57M
16.18M
7.03%
6.08%
1.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
KELOWNA